GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CRSP · Dec 31, 2025

CRISPR Therapeutics AG. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-048957General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

26.04% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-9829.46% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-90.59% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-18933.65% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

8114.13% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2065.50% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History5 statesHistory building

Jun 30, 20250/6 normalizedLevel 3 Sep 30, 20250/6 normalizedLevel 3 Dec 31, 20250/6 normalizedLevel 3 Mar 31, 20260/7 normalizedLevel 3 Jun 30, 20265/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 8.32%
Current: 26.04%
Delta: 17.72%

Cash Generation Decreased

Previous: -9520.14%
Current: -9829.46%
Delta: -309.32%

Growth Decreased

Previous: 47.67%
Current: -90.59%
Delta: -138.27%

Profitability Decreased

Previous: -14854.78%
Current: -18933.65%
Delta: -4078.87%

R And D Intensity Increased

Previous: 6625.65%
Current: 8114.13%
Delta: 1488.48%

Sbc Intensity Increased

Previous: 1867.72%
Current: 2065.50%
Delta: 197.78%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · CRSP Fundamental State →Has State · CRISPR Therapeutics AG →Transitioned To · CRSP Fundamental State →Transitioned To · CRSP CAPEX_INTENSITY_INCREASED →Transitioned To · CRSP CASH_GENERATION_DECREASED →Transitioned To · CRSP GROWTH_DECREASED →Transitioned To · CRSP PROFITABILITY_DECREASED →Transitioned To · CRSP R_AND_D_INTENSITY_INCREASED →Transitioned To · CRSP SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.